Clinical evolution of allo-SCT recipients in the myeloablative and RIC arms of the trial
| . | Myeloablative . | RIC . | P . |
|---|---|---|---|
| Acute GVHD grade II-IV, % (95% CI) | 51.9 (42.1-61.8) | 11.3 (1.6-21.2) | < .0001 |
| Chronic GVHD, % (95% CI) | 45.8 (34.8-56.7) | 41.7 (24.7-58.6) | NS (.83) |
| Cumulative incidence of NRM, % (95% CI), mo | |||
| 36 | 12.9 (7.5-19.7) | 4.2 (0.7-12.9) | NS (.33) |
| 72 | 15.8 (9.8-23.2) | 6.5 (0.2-16.2) | |
| 108 | 15.8 (9.8-23.2) | 6.5 (0.2-16.2) | |
| Cumulative incidence of relapse, % (95% CI), mo | |||
| 36 | 18.9 (12.4-26.6) | 20.7 (15.7-41) | NS (.33) |
| 72 | 21.7 (13.9-28.6) | 28.6 (16.5-43.4) | |
| 108 | 21.7 (13.9-28.6) | 28.6 (16.5-43.4) | |
| EFS, % (95% CI), mo | |||
| 36 | 68.1 (59.5-76.4) | 68.1 (54.6-80.9) | |
| 72 | 63.4 (54.6-72.2) | 65.8 (52.2-72.2) | NS (.83) |
| 108 | 63.4 (54.6-72.2) | 65.8 (52.2-72.2) | |
| OS, % (95% CI), mo | |||
| 36 | 73.4 (65.2-81.1) | 76.2 (63.1-87.3) | |
| 72 | 68 (59.3-76.3) | 69.3 (55.6-82.1) | NS (.82) |
| 108 | 68 (59.3-76.3) | 69.3 (55.6-82.1) |
| . | Myeloablative . | RIC . | P . |
|---|---|---|---|
| Acute GVHD grade II-IV, % (95% CI) | 51.9 (42.1-61.8) | 11.3 (1.6-21.2) | < .0001 |
| Chronic GVHD, % (95% CI) | 45.8 (34.8-56.7) | 41.7 (24.7-58.6) | NS (.83) |
| Cumulative incidence of NRM, % (95% CI), mo | |||
| 36 | 12.9 (7.5-19.7) | 4.2 (0.7-12.9) | NS (.33) |
| 72 | 15.8 (9.8-23.2) | 6.5 (0.2-16.2) | |
| 108 | 15.8 (9.8-23.2) | 6.5 (0.2-16.2) | |
| Cumulative incidence of relapse, % (95% CI), mo | |||
| 36 | 18.9 (12.4-26.6) | 20.7 (15.7-41) | NS (.33) |
| 72 | 21.7 (13.9-28.6) | 28.6 (16.5-43.4) | |
| 108 | 21.7 (13.9-28.6) | 28.6 (16.5-43.4) | |
| EFS, % (95% CI), mo | |||
| 36 | 68.1 (59.5-76.4) | 68.1 (54.6-80.9) | |
| 72 | 63.4 (54.6-72.2) | 65.8 (52.2-72.2) | NS (.83) |
| 108 | 63.4 (54.6-72.2) | 65.8 (52.2-72.2) | |
| OS, % (95% CI), mo | |||
| 36 | 73.4 (65.2-81.1) | 76.2 (63.1-87.3) | |
| 72 | 68 (59.3-76.3) | 69.3 (55.6-82.1) | NS (.82) |
| 108 | 68 (59.3-76.3) | 69.3 (55.6-82.1) |
Clinical evolution of allo-SCT recipients in the myeloablative and RIC arms of the trial shows similar evolution except for the higher incidence of acute GVHD in patients receiving a myealoablative conditioning regimen.
SCT indicates stem cell transplantation; RIC, reduced-intensity conditioning; CI, confidence interval; NS, non significant; NRM, nonrelapse mortality; EFS, event-free survival; and OS, overall survival.